Form 4: BeOne Medicines Director Wang Xiaodong Receives Equity Grant

Director and Scientific Advisory Board Chair Wang Xiaodong was granted 99,892 restricted share units and 193,492 stock options.

Summary

• Director Wang Xiaodong acquired 99,892 restricted share units (RSUs) on June 11, 2026.
• The director was also granted 193,492 stock options with an exercise price of $20.81 per share.
• The RSU grant vests over four years, with 25% vesting on each anniversary of June 11, 2026.
• The stock options vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.
• Following these transactions, the director's direct beneficial ownership of ordinary shares increased to 4,682,493.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership in the Scientific Advisory Board.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing relationship with the company.
• Market price volatility could impact the value of the granted options relative to the $20.81 exercise price.

Future Outlook

The equity grants are subject to continued service over a four-year vesting period, indicating an expectation of long-term involvement by the director.

Management Comments

• The grants are subject to accelerated vesting upon certain termination events.

Industry Context

StockSavvy.ai notes that equity grants to directors and scientific advisory board members are standard practice in the biotechnology sector to ensure alignment with long-term R&D and clinical milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive and director equity compensation in the biotech industry.
• The use of both RSUs and stock options is a common dual-incentive structure used by peer companies to balance retention and performance-based rewards.

Related Party Transactions

• The reporting person discloses indirect ownership through a family trust, an investment LLC, and a spouse, though the reporting person disclaims beneficial ownership of these holdings.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options and vesting of units.

Next Steps

• Vesting of 25% of RSUs on June 11, 2027.
• Vesting of 25% of stock options on June 11, 2027.

Key Dates

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Equity Compensation, Director Compensation